國家醫保藥品目錄調整 14種獨家藥均降逾43%
據《證券時報》報道,國家醫療保障局、人力資源和社會保障部公布《國家基本醫療保險、工傷保險和生育保險藥品目錄(2020年)》,將於明年3月1日起正式實施。
此次調整共對162種藥品進行談判,119種談判成功,其中包括96個獨家藥品,談判成功率高達73.46%。談判成功的藥品均價降幅過半。
此次調整首次設立目錄內藥品降價談判,進一步降低價格或費用偏高、基金佔用較多的14種獨家藥品。這些藥品單藥的年銷售金額均超過10億元人民幣。談判後,這些藥品成功留在目錄內,惟均價降43.46%。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.